A Randomized Phase III Trial of Oxaliplatin (OXAL) Plus 5-Fluorouracil (5-FU)/Leucovorin (CF) With or Without Cetuximab (C225) After Curative Resection for Patients With Stage III Colon Cancer
Latest Information Update: 30 Jun 2023
At a glance
- Drugs Cetuximab (Primary) ; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
- Indications Adenocarcinoma; Colon cancer
- Focus Registrational; Therapeutic Use
- Acronyms Alliance
- 06 Jun 2023 Results presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 06 Jun 2023 Results assessing the pathological analysis of tumor microenvironmental features using deep learning to predict survival of colon carcinomas, presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
- 07 Jun 2022 Results assessing the interaction between tumor-infiltrating lymphocytes and tumor sidedness in relationship to disease-free survival, presented at the 58th Annual Meeting of the American Society of Clinical Oncology.